Advances in Gene Therapy for Retinal Diseases
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 75
Special Issue Editor
Interests: gene therapy; neovascular age-related macular degeneration; diabetic retinopathy; central serous chorioretinopathy; metabolomics
Special Issue Information
Dear Colleagues,
The eye is considered an effective target for gene therapy due to its immune privileged status. Over the last few decades, there have been major strides made in the development of gene therapy for retinal diseases. In 2017, Luxturna was the first FDA-approved gene therapy in the United States for the treatment of Lebers Congenital Amaurosis Type 2. At present, there are several active gene therapy clinical trials for retinal conditions, including inherited retinal degenerations (IRDs), age-related macular degeneration and diabetic retinopathy. Gene therpies have shown promise in patients with IRDs where no alternate treatment options exist and in patients with neovascular age-related macular degeneration and diabetic retinopathy, where they present more durable and longer acting treatment options with the potential to decrease treatment burden and improve long-term clinical outcomes. Although gene therapy has the potential to revolutionize the way we treat patients with retinal diseases, we need to be mindful of the many challenges pertaining to drug safety/immunity, manufacturing/access and long term effects on ocular and systemic health.
This Special Issue aims to publish original articles that increase our undertanding of gene therapy in the treatment of retinal diseases. Submissions of review articles are also welcome.
Dr. Tahreem Aman Mir
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene therapy
- inherited retinal degenerations
- age-related macular degeneration
- diabetic retinopathy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
